Table 1.
Biomarkers for biological therapies
| Biologic | Criteria for prescriptiona | Limitations | References |
|---|---|---|---|
| Omalizumab (anti- IgE) |
|
17,27,32, 33, 34, 35, 36, 37, 38 | |
| Mepolizumab (Anti-IL5) | Blood eosinophil count ≥300 cells/μL, or blood eosinophil count ≥150 cells/μL in patients with well characterized eosinophilic asthma or requiring regular OCS |
|
17,27,37, 38, 39, 40, 41 |
| Benralizumab (anti-IL5 Ra) | Blood eosinophil ≥300/μL | ||
| Dupilumab (Anti-IL4R) | Peripheral eosinophilia (≥150 cells/μL), and/or FeNO >25 ppb |
|
17,37, 38, 39, 40, 41, 42 |
| Tezepelumab (anti-TSLP) |
|
|
32,43 |
FeNO: fractional exhaled nitric oxide; FEV1: forced expiratory volume in 1 s; ppb: part per billion; TSLP: thymic stromal lymphopoietin.
In addition to the diagnosis of severe asthma.
Would predict better response.